vs
Apellis Pharmaceuticals, Inc.（APLS）与FORMFACTOR INC（FORM）财务数据对比。点击上方公司名可切换其他公司
FORMFACTOR INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.1倍（$226.1M vs $199.9M），FORMFACTOR INC净利率更高（9.0% vs -29.5%，领先38.5%），FORMFACTOR INC同比增速更快（32.0% vs -5.9%），FORMFACTOR INC自由现金流更多（$30.7M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 7.0%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
FormFactor Inc.总部位于美国加利福尼亚州利弗莫尔，是集成电路测试测量技术领域的知名供应商，面向半导体行业客户提供各类专业产品，助力客户优化器件性能，提升芯片研发与生产环节的测试效率。
APLS vs FORM — 直观对比
营收规模更大
FORM
是对方的1.1倍
$199.9M
营收增速更快
FORM
高出37.9%
-5.9%
净利率更高
FORM
高出38.5%
-29.5%
自由现金流更多
FORM
多$45.0M
$-14.3M
两年增速更快
APLS
近两年复合增速
7.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $226.1M |
| 净利润 | $-59.0M | $20.4M |
| 毛利率 | — | 38.4% |
| 营业利润率 | -25.6% | 7.4% |
| 净利率 | -29.5% | 9.0% |
| 营收同比 | -5.9% | 32.0% |
| 净利润同比 | -62.2% | 218.5% |
| 每股收益（稀释后） | $-0.40 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSFORM
| Q1 26 | — | $226.1M | ||
| Q4 25 | $199.9M | $215.2M | ||
| Q3 25 | $458.6M | $202.7M | ||
| Q2 25 | $178.5M | $195.8M | ||
| Q1 25 | $166.8M | $171.4M | ||
| Q4 24 | $212.5M | $189.5M | ||
| Q3 24 | $196.8M | $207.9M | ||
| Q2 24 | $199.7M | $197.5M |
净利润APLSFORM
| Q1 26 | — | $20.4M | ||
| Q4 25 | $-59.0M | $23.2M | ||
| Q3 25 | $215.7M | $15.7M | ||
| Q2 25 | $-42.2M | $9.1M | ||
| Q1 25 | $-92.2M | $6.4M | ||
| Q4 24 | $-36.4M | $9.7M | ||
| Q3 24 | $-57.4M | $18.7M | ||
| Q2 24 | $-37.7M | $19.4M |
毛利率APLSFORM
| Q1 26 | — | 38.4% | ||
| Q4 25 | — | 42.2% | ||
| Q3 25 | — | 39.8% | ||
| Q2 25 | — | 37.3% | ||
| Q1 25 | — | 37.7% | ||
| Q4 24 | — | 38.8% | ||
| Q3 24 | — | 40.7% | ||
| Q2 24 | — | 44.0% |
营业利润率APLSFORM
| Q1 26 | — | 7.4% | ||
| Q4 25 | -25.6% | 10.9% | ||
| Q3 25 | 48.7% | 8.9% | ||
| Q2 25 | -18.6% | 6.3% | ||
| Q1 25 | -50.0% | 1.9% | ||
| Q4 24 | -12.3% | 4.1% | ||
| Q3 24 | -24.0% | 8.6% | ||
| Q2 24 | -14.7% | 9.0% |
净利率APLSFORM
| Q1 26 | — | 9.0% | ||
| Q4 25 | -29.5% | 10.8% | ||
| Q3 25 | 47.0% | 7.7% | ||
| Q2 25 | -23.6% | 4.6% | ||
| Q1 25 | -55.3% | 3.7% | ||
| Q4 24 | -17.1% | 5.1% | ||
| Q3 24 | -29.2% | 9.0% | ||
| Q2 24 | -18.9% | 9.8% |
每股收益（稀释后）APLSFORM
| Q1 26 | — | $0.26 | ||
| Q4 25 | $-0.40 | $0.29 | ||
| Q3 25 | $1.67 | $0.20 | ||
| Q2 25 | $-0.33 | $0.12 | ||
| Q1 25 | $-0.74 | $0.08 | ||
| Q4 24 | $-0.30 | $0.12 | ||
| Q3 24 | $-0.46 | $0.24 | ||
| Q2 24 | $-0.30 | $0.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $123.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $1.1B |
| 总资产 | $1.1B | $1.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSFORM
| Q1 26 | — | $123.5M | ||
| Q4 25 | $466.2M | $103.3M | ||
| Q3 25 | $479.2M | $266.0M | ||
| Q2 25 | $370.0M | $249.3M | ||
| Q1 25 | $358.4M | $299.0M | ||
| Q4 24 | $411.3M | $360.0M | ||
| Q3 24 | $396.9M | $354.5M | ||
| Q2 24 | $360.1M | $357.6M |
总债务APLSFORM
| Q1 26 | — | — | ||
| Q4 25 | — | $12.2M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $13.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益APLSFORM
| Q1 26 | — | $1.1B | ||
| Q4 25 | $370.1M | $1.0B | ||
| Q3 25 | $401.2M | $1.0B | ||
| Q2 25 | $156.3M | $990.0M | ||
| Q1 25 | $164.2M | $965.9M | ||
| Q4 24 | $228.5M | $947.8M | ||
| Q3 24 | $237.1M | $955.0M | ||
| Q2 24 | $264.3M | $947.9M |
总资产APLSFORM
| Q1 26 | — | $1.3B | ||
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $821.4M | $1.2B | ||
| Q1 25 | $807.3M | $1.2B | ||
| Q4 24 | $885.1M | $1.1B | ||
| Q3 24 | $901.9M | $1.2B | ||
| Q2 24 | $904.5M | $1.2B |
负债/权益比APLSFORM
| Q1 26 | — | — | ||
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.01× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $45.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $30.7M |
| 自由现金流率自由现金流/营收 | -7.1% | 13.6% |
| 资本支出强度资本支出/营收 | 0.1% | 6.7% |
| 现金转化率经营现金流/净利润 | — | 2.21× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $37.5M |
8季度趋势，按日历期对齐
经营现金流APLSFORM
| Q1 26 | — | $45.0M | ||
| Q4 25 | $-14.2M | $46.0M | ||
| Q3 25 | $108.5M | $27.0M | ||
| Q2 25 | $4.4M | $18.9M | ||
| Q1 25 | $-53.4M | $23.5M | ||
| Q4 24 | $19.4M | $35.9M | ||
| Q3 24 | $34.1M | $26.7M | ||
| Q2 24 | $-8.3M | $21.9M |
自由现金流APLSFORM
| Q1 26 | — | $30.7M | ||
| Q4 25 | $-14.3M | $34.7M | ||
| Q3 25 | $108.3M | $19.5M | ||
| Q2 25 | $4.4M | $-47.4M | ||
| Q1 25 | $-53.4M | $5.0M | ||
| Q4 24 | $19.3M | $28.3M | ||
| Q3 24 | — | $17.8M | ||
| Q2 24 | $-8.4M | $13.5M |
自由现金流率APLSFORM
| Q1 26 | — | 13.6% | ||
| Q4 25 | -7.1% | 16.1% | ||
| Q3 25 | 23.6% | 9.6% | ||
| Q2 25 | 2.5% | -24.2% | ||
| Q1 25 | -32.0% | 2.9% | ||
| Q4 24 | 9.1% | 14.9% | ||
| Q3 24 | — | 8.6% | ||
| Q2 24 | -4.2% | 6.8% |
资本支出强度APLSFORM
| Q1 26 | — | 6.7% | ||
| Q4 25 | 0.1% | 5.3% | ||
| Q3 25 | 0.0% | 3.7% | ||
| Q2 25 | 0.0% | 33.8% | ||
| Q1 25 | 0.0% | 10.8% | ||
| Q4 24 | 0.0% | 4.0% | ||
| Q3 24 | 0.0% | 4.3% | ||
| Q2 24 | 0.0% | 4.3% |
现金转化率APLSFORM
| Q1 26 | — | 2.21× | ||
| Q4 25 | — | 1.98× | ||
| Q3 25 | 0.50× | 1.72× | ||
| Q2 25 | — | 2.08× | ||
| Q1 25 | — | 3.68× | ||
| Q4 24 | — | 3.70× | ||
| Q3 24 | — | 1.43× | ||
| Q2 24 | — | 1.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
FORM
暂无分部数据
